Global Colorectal Cancer Drugs Market US$ 6.9 Billion by 2021

The global colorectal cancer drugs market expected to reach US$ 6.9 billion by 2021, growing at CAGR 2.3% over the forecast period 2017-2021, mainly due to colorectal polyps screening and improved treatment over the last few decades.

Colorectal cancer is a leading cause of cancer-related deaths. Targeted therapy drugs for colorectal cancer include anti- vascular endothelial growth factor (VEGF) therapies that stops VEGF from forming new blood vessels and pass nutrients to tumor cells (also known as, anti-angiogenesis therapy). These include monoclonal antibody therapy such as, Bevacizumab (Avastin), Ramucirumab (Cyramza), Ziv-aflibercept (Zaltrap), and Ramucirumab (Cyramza). Anti- epidermal growth factor receptor (EGFR) therapies target EGFR protein that often appears in high amounts on the surface of cancer cells and helps them grow. These include: Cetuximab (Erbitux), and Panitumumab (Vectibix). Regorafenib (Stivarga) is a type of targeted therapy known as a kinase inhibitor, used to treat advanced colorectal cancer. It blocks several kinase proteins that either help tumor cells grow or help form new blood vessels to feed the tumor. Immune checkpoint inhibitors such as Pembrolizumab (Keytruda) targets PD-1, a protein on immune system cells that normally prevents cells from attacking other cells in the body. Some common chemotherapy drugs used for colorectal cancer include: 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Trifluridine and tipiracil (Lonsurf). Dabrafenib and trametinib, the first BRAF and MEK inhibitor combination drugs are in clinical development.

Browse Colorectal Cancer Drugs Market by Drug Class - Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, B-Raf Kinase (BRAF) or MEK Inhibitors - Mitogen-activated Protein Kinase (MAPK) / Extracellular Signal-Regulated Kinase (ERK), Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, Chemotherapies and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/

The global colorectal cancer drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global colorectal cancer drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global colorectal cancer drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global colorectal cancer drugs market and profiled in this report include AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Genentech (Roche), Hutchison MediPharma, Merck & Co., Mologen, Regeneron, Sanofi, Sumitomo Dainippon, Taiho Pharmaceutical, and Vaccinogen.

1. Drug Class
1.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
1.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
1.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
1.4. BRAF or MEK Inhibitors (MAPK/ERK kinase)
1.5. Tyrosine Kinase (TKI) Inhibitors
1.6. Immunomodulators
1.7. Chemotherapies

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. AB Science
3.2. Amgen
3.3. Array BioPharma
3.4. Bayer
3.5. Boehringer Ingelheim
3.6. Bristol-Myers Squibb
3.7. Elli Lilly
3.8. Genentech (Roche)
3.9. Hutchison MediPharma
3.10. Merck & Co.
3.11. Mologen
3.12. Regeneron
3.13. Sanofi
3.14. Sumitomo Dainippon
3.15. Taiho Pharmaceutical
3.16. Vaccinogen

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.